{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:16:18Z","timestamp":1765995378229,"version":"3.40.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.intimp.2024.112417","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T09:23:21Z","timestamp":1718702601000},"page":"112417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery"],"prefix":"10.1016","volume":"137","author":[{"given":"Yin-Shuang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Wen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang-Yu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo-Nan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-Ming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing-Fu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-5957","authenticated-orcid":false,"given":"Guo-Qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112417_b0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"issue":"7","key":"10.1016\/j.intimp.2024.112417_b0010","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.intimp.2024.112417_b0015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.intimp.2024.112417_b0020","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1016\/j.intimp.2024.112417_b0025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MIB.0b013e31828029c0","article-title":"Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies","volume":"19","author":"Lutgens","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.intimp.2024.112417_b0030","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cgh.2020.08.015","article-title":"The risk of extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies","volume":"19","author":"Lo","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.intimp.2024.112417_b0035","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.crohns.2011.04.013","article-title":"Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European collaborative follow-up study","volume":"5","author":"Katsanos","year":"2011","journal-title":"J Crohns Colitis"},{"issue":"9","key":"10.1016\/j.intimp.2024.112417_b0040","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.1200\/JOP.19.00672","article-title":"Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis","volume":"16","author":"Grover","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"10.1016\/j.intimp.2024.112417_b0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis","volume":"66","author":"Bergqvist","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.intimp.2024.112417_b0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2024.112417_b0055","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"K\u00e4hler","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"10.1016\/j.intimp.2024.112417_b0060","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00384-020-03638-3","article-title":"Remission of ulcerative colitis flare-up induced by nivolumab","volume":"35","author":"Iwamoto","year":"2020","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.intimp.2024.112417_b0065","article-title":"A self-indicating cellulose-based gel with tunable performance for bioactive agent delivery","volume":"63","author":"Wing-Fu","year":"2021","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"10.1016\/j.intimp.2024.112417_b0070","article-title":"A gel-forming clusteroluminogenic polymer with tunable emission behavior as a sustained-release carrier enabling real-time tracking during bioactive agent delivery","volume":"21","author":"Wing-Fu","year":"2020","journal-title":"Applied Materials Today"},{"key":"10.1016\/j.intimp.2024.112417_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.apmt.2020.100876","article-title":"A gel-forming clusteroluminogenic polymer with tunable emission behavior as a sustained-release carrier enabling real-time tracking during bioactive agent delivery","volume":"21","author":"Lai","year":"2020","journal-title":"Applied Materials Today"},{"key":"10.1016\/j.intimp.2024.112417_b0080","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4504936","article-title":"Antitumor effects of curcumin and glycyrrhetinic acid-modified curcumin-loaded cationic liposome by intratumoral administration","volume":"2020","author":"Chang","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"issue":"8","key":"10.1016\/j.intimp.2024.112417_b0085","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1002\/ptr.7538","article-title":"Preclinical studies of the antitumor effect of curcumin-loaded polymeric nanocapsules: a systematic review and meta-analysis","volume":"36","author":"de Oliveira","year":"2022","journal-title":"Phytother Res"},{"issue":"3","key":"10.1016\/j.intimp.2024.112417_b0090","doi-asserted-by":"crossref","first-page":"716","DOI":"10.14336\/AD.2022.1101","article-title":"Pharmacological mechanisms and clinical applications of curcumin: update","volume":"14","author":"Hao","year":"2023","journal-title":"Aging Dis"},{"issue":"14","key":"10.1016\/j.intimp.2024.112417_b0095","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-08-0024","article-title":"Phase II trial of curcumin in patients with advanced pancreatic cancer","volume":"14","author":"Dhillon","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.intimp.2024.112417_b0100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1158\/1940-6207.CAPR-11-0060","article-title":"Curcumin chemoprevention: the long road to clinical translation","volume":"4","author":"Shureiqi","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"10.1016\/j.intimp.2024.112417_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01635581.2022.2096909","article-title":"Complexity of tumor microenvironment: therapeutic role of curcumin and its metabolites","volume":"75","author":"Prasad","year":"2023","journal-title":"Nutr Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.112417_b0110","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1080\/10717544.2021.1921077","article-title":"Synergistic effect of the anti-PD-1 antibody with blood stable and reduction sensitive curcumin micelles on colon cancer","volume":"28","author":"Gong","year":"2021","journal-title":"Drug Deliv"},{"key":"10.1016\/j.intimp.2024.112417_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119359","article-title":"Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma","volume":"279","author":"Guo","year":"2021","journal-title":"Life Sci"},{"issue":"12","key":"10.1016\/j.intimp.2024.112417_b0120","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1111\/cas.14675","article-title":"Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3","volume":"111","author":"Hayakawa","year":"2020","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.intimp.2024.112417_b0125","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/aps.2017.185","article-title":"Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages","volume":"39","author":"Yan","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.intimp.2024.112417_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109847","article-title":"Puerarin inhibits inflammation and oxidative stress in dextran sulfate sodium-induced colitis mice model","volume":"124","author":"Jeon","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.intimp.2024.112417_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/ph14040367","article-title":"Checkpoint inhibitor-induced colitis-a clinical overview of incidence, prognostic implications and extension of current treatment options","volume":"14","author":"Portenkirchner","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2024.112417_b0140","doi-asserted-by":"crossref","DOI":"10.1080\/08916934.2023.2259126","article-title":"Oncolytic virus oHSV2 combined with PD-1\/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment","volume":"56","author":"Zhang","year":"2023","journal-title":"Autoimmunity"},{"issue":"6","key":"10.1016\/j.intimp.2024.112417_b0145","doi-asserted-by":"crossref","first-page":"355.e21","DOI":"10.1016\/j.urolonc.2019.03.003","article-title":"Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab","volume":"37","author":"Ishihara","year":"2019","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"10.1016\/j.intimp.2024.112417_b0150","article-title":"Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK","volume":"72","author":"Reinmuth","year":"2018","journal-title":"Pneumologie"},{"issue":"36","key":"10.1016\/j.intimp.2024.112417_b0155","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.intimp.2024.112417_b0160","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.intimp.2024.112417_b0165","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","article-title":"The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes","volume":"185","author":"Huang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.112417_b0170","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.imlet.2021.03.001","article-title":"Increased circulating PD-1(hi)CXCR5- peripheral helper T cells are associated with disease severity of active ulcerative colitis patients","volume":"233","author":"Long","year":"2021","journal-title":"Immunol Lett"},{"key":"10.1016\/j.intimp.2024.112417_b0175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-015-0064-2","article-title":"Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis","volume":"3","author":"Bostwick","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2024.112417_b0180","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1007\/s00520-020-05707-3","article-title":"Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors","volume":"28","author":"Dougan","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.intimp.2024.112417_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953761","article-title":"Safety and efficacy of programmed cell death 1 and programmed death ligand-1 inhibitors in the treatment of cancer: an overview of systematic reviews","volume":"13","author":"Ou","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2024.112417_b0190","first-page":"62","article-title":"Over-expression of immunosuppressive molecules, PD-L1 and PD-L2 ulcerative colitis patients","volume":"16","author":"Rajabian","year":"2019","journal-title":"Iran J Immunol"},{"issue":"8","key":"10.1016\/j.intimp.2024.112417_b0195","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/1061186X.2017.1401076","article-title":"Novel advances in targeted drug delivery","volume":"26","author":"\u00d6zt\u00fcrk-Atar","year":"2018","journal-title":"J Drug Target"},{"issue":"3","key":"10.1016\/j.intimp.2024.112417_b0200","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1021\/jacs.5b09974","article-title":"Emerging frontiers in drug delivery","volume":"138","author":"Tibbitt","year":"2016","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.intimp.2024.112417_b0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jconrel.2020.04.005","article-title":"Targeted drug delivery therapies inspired by natural taxes","volume":"322","author":"Nguyen","year":"2020","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.intimp.2024.112417_b0210","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004695","article-title":"Therapeutic targeting of PD-1\/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment","volume":"10","author":"Ac\u00farcio","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2024.112417_b0215","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1158\/2326-6066.CIR-19-0744","article-title":"SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an anti-PD-1-resistant model of non-small cell lung cancer","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol Res"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692400938X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692400938X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T15:34:12Z","timestamp":1720280052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692400938X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":43,"alternative-id":["S156757692400938X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112417","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112417"}}